{"data":{"type":"company_profile_ai","id":29542,"entity_id":"wefunder:company:29542","attributes":{"canonical_url":"https://wefunder.com/neurocarrus","retrieval_urls":{"canonical":"https://wefunder.com/neurocarrus","json":"https://wefunder.com/neurocarrus.json","markdown":"https://wefunder.com/neurocarrus.md","ai_json":"https://wefunder.com/neurocarrus.ai.json","ai_text":"https://wefunder.com/neurocarrus.ai.txt","changelog_json":"https://wefunder.com/neurocarrus.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-09T05:00:09Z","generated_at":"2026-06-09T20:24:07Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"company":{"id":29542,"entity_id":"wefunder:company:29542","slug":"neurocarrus","name":"Neurocarrus","tagline":"Treating Neurodegenerative Disease and Pain \r\nWithout Addiction","elevator_pitch":"Since 2017 the opioid epidemic has been classified as\u0026nbsp;national emergency. We're developing a non-opioid drug to treat pain without risk of addiction. So far\u0026nbsp;we've shown promising results\u0026nbsp;in animal trials and are fundraising to continue pre-clinical development.\u0026nbsp;","location":"Monterey, CA","website":"https://neurocarrus.com/","total_amount_raised":544228,"total_investors":615,"is_funded":true,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 544228","citation":"https://wefunder.com/neurocarrus#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-09T05:00:09Z","as_of":"2026-06-09T20:24:07Z","confidence":"high"},"observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-10T05:00:09Z"},{"claim_id":"claim-total-investors","text":"Total investors: 615","citation":"https://wefunder.com/neurocarrus#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-09T05:00:09Z","as_of":"2026-06-09T20:24:07Z","confidence":"high"},"observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-10T05:00:09Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 544228","citation":"https://wefunder.com/neurocarrus#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-09T05:00:09Z","as_of":"2026-06-09T20:24:07Z","confidence":"high"},"observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-10T05:00:09Z"},{"claim_id":"claim-total-investors","text":"Total investors: 615","citation":"https://wefunder.com/neurocarrus#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-09T05:00:09Z","as_of":"2026-06-09T20:24:07Z","confidence":"high"},"observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-10T05:00:09Z"}],"company_claims":{"tagline":"Treating Neurodegenerative Disease and Pain \r\nWithout Addiction","elevator_pitch":"Since 2017 the opioid epidemic has been classified as\u0026nbsp;national emergency. We're developing a non-opioid drug to treat pain without risk of addiction. So far\u0026nbsp;we've shown promising results\u0026nbsp;in animal trials and are fundraising to continue pre-clinical development.\u0026nbsp;","story":"Neurocarrus top scientific publications:Animal efficacy and safety studiesTargeting, mechanism, and efficacy studiesDrug design and engineering studies","quick_facts":["Drug candidate N-001 provides relief from acute pain in animals caused by inflammation or surgery.","Neurocarrus has built a pipeline of drugs using the APOLLO targeting and delivery system.","N-001, NL-17, N-19a treat acute, migraine and chronic pain by sensory neuron targeting.","The APOLLO drugs use a unique manufacturing process to discourage competitors.","There is a massive market for the treatment of Neurodegenerative disease and pain around the world.","Neurocarrus has a strong track record of non-dilutive funding from federal and state government.","Founder has been working in the space for 25+ years trouble shooting commercial biologicals.","Patents issued and pending on exclusively licensed technology in both the U.S. and select countries."]},"computed_metrics":{"total_amount_raised":544228,"total_investors":615,"team_size":6,"featured_investor_count":1,"faq_count":5,"recent_post_count":0},"quick_facts":[{"claim_id":"claim-fact-1","value":"Drug candidate N-001 provides relief from acute pain in animals caused by inflammation or surgery.","citation":"https://wefunder.com/neurocarrus#claim-fact-1","observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-16T05:00:09Z"},{"claim_id":"claim-fact-2","value":"Neurocarrus has built a pipeline of drugs using the APOLLO targeting and delivery system.","citation":"https://wefunder.com/neurocarrus#claim-fact-2","observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-16T05:00:09Z"},{"claim_id":"claim-fact-3","value":"N-001, NL-17, N-19a treat acute, migraine and chronic pain by sensory neuron targeting.","citation":"https://wefunder.com/neurocarrus#claim-fact-3","observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-16T05:00:09Z"},{"claim_id":"claim-fact-4","value":"The APOLLO drugs use a unique manufacturing process to discourage competitors.","citation":"https://wefunder.com/neurocarrus#claim-fact-4","observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-16T05:00:09Z"},{"claim_id":"claim-fact-5","value":"There is a massive market for the treatment of Neurodegenerative disease and pain around the world.","citation":"https://wefunder.com/neurocarrus#claim-fact-5","observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-16T05:00:09Z"},{"claim_id":"claim-fact-6","value":"Neurocarrus has a strong track record of non-dilutive funding from federal and state government.","citation":"https://wefunder.com/neurocarrus#claim-fact-6","observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-16T05:00:09Z"},{"claim_id":"claim-fact-7","value":"Founder has been working in the space for 25+ years trouble shooting commercial biologicals.","citation":"https://wefunder.com/neurocarrus#claim-fact-7","observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-16T05:00:09Z"},{"claim_id":"claim-fact-8","value":"Patents issued and pending on exclusively licensed technology in both the U.S. and select countries.","citation":"https://wefunder.com/neurocarrus#claim-fact-8","observed_at":"2026-06-09T05:00:09Z","expires_at":"2026-06-16T05:00:09Z"}],"latest_fundraise":{"id":66105,"entity_id":"wefunder:fundraise:66105","state":"successful","offering_type":"4(a)(6)","structure":"safe","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2024-06-12T01:23:08Z","funding_closed_at":"2026-05-01T03:59:59Z"},"investor_memos":[],"team":[{"id":318737,"entity_id":"wefunder:company_role:318737","name":"Paul Blum","title":"Co-founder/CEO","role":"founder","profile_url":"https://wefunder.com/paulblum"},{"id":3856440,"entity_id":"wefunder:company_role:3856440","name":"Derek Allen","title":"Research Scientist","role":"employee"},{"id":342466,"entity_id":"wefunder:company_role:342466","name":"Jianguo Cheng, MD, Ph.D","title":"Board Member","role":"employee"},{"id":3867080,"entity_id":"wefunder:company_role:3867080","name":"Bruce McDonald, JD","title":"Board Member","role":"employee"},{"id":3867081,"entity_id":"wefunder:company_role:3867081","name":"Mark Blum, JD","title":"Board Member","role":"employee"},{"id":3872247,"entity_id":"wefunder:company_role:3872247","name":"Vicky Valverde Salas","title":"Board Member","role":"employee","profile_url":"https://wefunder.com/vicky.valverde.salas"}],"featured_investors":[{"id":8840,"entity_id":"wefunder:company_investor_profile:8840","name":"Kurt Stahlfeld","profile_url":"https://wefunder.com/kurtstahlfeld","endorsement_quote":"I believe that Neurocarrus has the potential to revolutionize pain management. Paul and his team have created an incredibly clever drug the produces long lasting pain relief with no side effects or possibility of addiction. Neurocarrus’s N-001 has the potential to become the new standard of care for pain management, improving patient outcomes while eliminating the risk of opioid addiction. With backing from the National Institutes of Health, Neurocarrus is well on their way to changing the world of pain management and capturing a large portion of a market that approaches $80B/year."}],"relationships":[{"source_entity_id":"wefunder:company:29542","relation":"has_team_member","target_entity_id":"wefunder:user:185640","target_url":"https://wefunder.com/paulblum"},{"source_entity_id":"wefunder:company:29542","relation":"has_team_member","target_entity_id":"wefunder:company_role:3856440"},{"source_entity_id":"wefunder:company:29542","relation":"has_team_member","target_entity_id":"wefunder:company_role:342466"},{"source_entity_id":"wefunder:company:29542","relation":"has_team_member","target_entity_id":"wefunder:company_role:3867080"},{"source_entity_id":"wefunder:company:29542","relation":"has_team_member","target_entity_id":"wefunder:company_role:3867081"},{"source_entity_id":"wefunder:company:29542","relation":"has_team_member","target_entity_id":"wefunder:user:4149782","target_url":"https://wefunder.com/vicky.valverde.salas"},{"source_entity_id":"wefunder:company:29542","relation":"has_featured_investor","target_entity_id":"wefunder:user:83595","target_url":"https://wefunder.com/kurtstahlfeld"},{"source_entity_id":"wefunder:company:29542","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:66105"}],"faq":[{"question":"What was the valuation on your 12/17 priced round? Why crowdfunding vs. traditional public biotech listings on the OTC or Canadian Venture exchanges? Do you have IP that's defendable? Thanks for your time, I like what you're trying to accomplish!","answer":"Hello Barnaby, happy to answer these. Our valuation in our 12/17 round was 3 million. We chose crowdfunding on Wefunder due to the number of people who have contacted us individually and expressed a desire to invest at a small scale. Many acquaintances expressed interest to us since our inception, but we haven't had the time to individually work through each contract. Using Wefunder, we can give each party a full picture and make sure they are completely informed, while providing a simple way..."},{"question":"Interesting molecule that from the limited information appears to work by blocking pain neurotransmission-Is this then a drug for neuropathic or somatic pain or both? secondly venturing in to phase 1-3 trials requires huge funding and we have seen many biotech start up firms o...","answer":"Hello Palliankal. Thanks for reaching out. Your understanding is essentially correct: our drug targets overactive sensory neurons, and has the potential to treat many kinds of peripheral pain. So to answer your first question, it is a drug for both kinds of pain. In regards to your second question, I assume you're asking about how we will fund clinical trials. We anticipate U.S. government grant support for Phase 1 trials (especially given newly allocated funding for development of new, non-o..."},{"question":"What is your exit strategy? Do you intend to pay a dividend past Phase three?","answer":"Hello Craig. We plan to partner with a larger pharmaceutical company at or after Phase 1 clinical trials. This will be either through a licensing agreement for N-001, or an acquisition of our company. Dividend payments, or other form of profit-sharing, will depend on the structure of our exit, but may come sooner than Phase 3."},{"question":"Hi, does the SAFE converts to preferred stock or common stock?","answer":"Good question. SAFE converts to preferred stock. Paul"},{"question":"Mr. Blum- How long(years) do you foresee before a larger pharmaceutical company purchases your drug. Asking as an investor for time frame. Thank you and good luck!","answer":"We could expect our drug to be purchased (or licensed) within 1-2 years corresponding to stages in its development. Stage one is when the FDA (Food and Drug Agency) approves our IND (Investigational New Drug) application because it means we can start human clinical trials. Stage two is when we complete Phase I human trials with a successful outcome, that would be that our drug is safe."}],"recent_posts":[],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-09T20:24:07Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-09T05:00:09Z","as_of":"2026-06-09T20:24:07Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-09T05:00:09Z","as_of":"2026-06-09T20:24:07Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-06-03T21:06:38Z","as_of":"2026-06-09T20:24:07Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-06-03T21:06:38Z","as_of":"2026-06-09T20:24:07Z","confidence":"medium"}}}}}}